SICKLE CELL DISEASE – SCI & TECH

News: How subpar treatment options allow sickle cell disease to persist | Explained

 

What's in the news?

       With essential drugs for Sickle Cell Disease (SCD) treatment unavailable at district healthcare institutions, there’s a rising worry regarding the hurdles encountered by marginalized Indigenous Tribal communities in handling SCD treatment.

 

Sickle Cell Disease (SCD):

       It is a hereditary haemoglobin disorder characterized by a genetic mutation causing red blood cells (RBCs) to take on a sickle or crescent shape rather than their normal round shape.

       This alteration leads to increased rigidity, hindering effective circulation and resulting in complications such as anaemia, organ damage, severe pain episodes and reduced lifespan.

 

Vulnerability of Tribal Populations:

       Marginalized tribal communities are particularly susceptible to SCD, as highlighted by the Ministry of Health and Family Welfare.

 

Common Symptoms:

       Symptoms include chronic anaemia leading to fatigue and weakness, painful episodes (sickle cell crisis) affecting bones and extremities and delayed growth and puberty.

 

Treatment Approaches:

       Blood Transfusions: Used to alleviate anaemia and reduce pain crises.

       Hydroxyurea: Medication aimed at decreasing painful episodes and preventing long-term complications.

       Gene Therapy: Includes bone marrow or stem cell transplantation, with methods like Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) being explored.

 

India’s Sickle Cell Disease Status:

       India ranks third globally in SCD births, with a significant portion occurring in tribal communities.

 

Government Initiatives:

       National Sickle Cell Anaemia Elimination Mission: Aims at reducing disease prevalence through screening and awareness campaigns.

       National Health Mission (NHM): Focuses on raising awareness and facilitating early detection and treatment.

       Research Initiatives: Including gene-editing therapies and stem cell research for SCD treatment.

       State-Level Programs: Such as the State Haemoglobinopathy Mission of Madhya Pradesh, targeting screening and management challenges.